Clinical Research Directory

Inclusion Criteria: 1. Age 18- 80 years, male or female； 2. mRS score ≤1 prior to this onset; 3. Planning to receive or have received intravascular recanalization therapy at our center within 24h of onset; 4. To complete the first administration of the investigational medication within 24h of onset; 5. NIHSS（National Institutes of Health Stroke Scale）score≥6 prior to intravascular recanalization; 6. Informed consent. Exclusion Criteria: 1. Intracranial hemorrhagic diseases, including hemorrhagic stroke, epidural hematoma, intracranial hematoma, ventricular hemorrhage, subarachnoid hemorrhage, etc.; 2. Severe disorders of consciousness: NIHSS 1a≥2 points; 3. Large infarct core (ASPECTS \<6, or\>1/3 of MCA territory involved, as evidenced by CT or MRI); 4. Severe hypertension: systolic blood pressure ≥185mmHg or diastolic blood pressure ≥110mmHg after medication control; 5. History of severe kidney disease (such as dialysis), or eGFR \<45 mL/min/1.73m²; 6. History of severe liver disease, or ALT, AST levels more than 3 times of the upper limit of normal, or bilirubin more than 3 times of the upper limit of normal; 7. Cardiovascular diseases, such as complete atrioventricular block, history of congestive heart failure (CHF), or heart function classification≥NYHA Class III; 8. Critically ill patients with an expected lifespan≤90 days; 9. History of epilepsy or epilepsy-like symptoms during stroke or severe psychiatric disorders, intellectual disability, or dementia; 10. History of intracranial hemorrhage; 11. Severe injury or surgery history within 3 months of onset; 12. Have received\>1 dose of neuroprotective drugs after this onset, such as edaravone, edaravone dexborneol injection, ginkgo lactone, ginkgo diterpene glucamine，etc; 13. Allergy to the investigational drug (either the active ingredient androtriol or the excipient hydroxypropyl beta-cyclodextrin) or similar chemical structure drugs; 14. Pregnant or breastfeeding; 15. Participation in other clinical trials within 3 months of onset; 16. Unsuitable for participating in this study judged by investigator.